Xbiotech Stock Current Liabilities
| XBIT Stock | USD 7.61 0.26 3.54% |
XBiotech fundamentals help investors to digest information that contributes to XBiotech's financial success or failures. It also enables traders to predict the movement of XBiotech Stock. The fundamental analysis module provides a way to measure XBiotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to XBiotech stock.
Total Current Liabilities is likely to gain to about 9.4 M in 2024, whereas Non Current Liabilities Total is likely to drop slightly above 870.2 K in 2024. XBiotech | Current Liabilities |
XBiotech Company Current Liabilities Analysis
XBiotech's Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current XBiotech Current Liabilities | 6.29 M |
Most of XBiotech's fundamental indicators, such as Current Liabilities, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, XBiotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
XBiotech Current Liabilities Driver Correlations
Understanding the fundamental principles of building solid financial models for XBiotech is extremely important. It helps to project a fair market value of XBiotech Stock properly, considering its historical fundamentals such as Current Liabilities. Since XBiotech's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of XBiotech's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of XBiotech's interrelated accounts and indicators.
Click cells to compare fundamentals
XBiotech Current Liabilities Historical Pattern
Today, most investors in XBiotech Stock are looking for potential investment opportunities by analyzing not only static indicators but also various XBiotech's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current liabilities growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of XBiotech current liabilities as a starting point in their analysis.
XBiotech Current Liabilities |
| Timeline |
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
XBiotech Total Current Liabilities
Total Current Liabilities |
|
In accordance with the recently published financial statements, XBiotech has a Current Liabilities of 6.29 M. This is 99.64% lower than that of the Biotechnology sector and 98.84% lower than that of the Health Care industry. The current liabilities for all United States stocks is 99.92% higher than that of the company.
XBiotech Current Valuation Drivers
We derive many important indicators used in calculating different scores of XBiotech from analyzing XBiotech's financial statements. These drivers represent accounts that assess XBiotech's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of XBiotech's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 726.9M | 482.4M | 334.4M | 106.8M | 122.9M | 116.7M | |
| Enterprise Value | 12.3M | 245.0M | 97.4M | (50.5M) | (58.0M) | (55.1M) |
XBiotech ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, XBiotech's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to XBiotech's managers, analysts, and investors.Environmental | Governance | Social |
XBiotech Fundamentals
| Return On Equity | -0.16 | ||||
| Return On Asset | -0.12 | ||||
| Current Valuation | 58.86 M | ||||
| Shares Outstanding | 30.48 M | ||||
| Shares Owned By Insiders | 35.10 % | ||||
| Shares Owned By Institutions | 16.18 % | ||||
| Number Of Shares Shorted | 848.26 K | ||||
| Price To Earning | 1.21 X | ||||
| Price To Book | 1.21 X | ||||
| Price To Sales | 12.23 X | ||||
| Revenue | 300 K | ||||
| Gross Profit | 3.36 M | ||||
| EBITDA | (35.77 M) | ||||
| Net Income | (24.56 M) | ||||
| Cash And Equivalents | 225.79 M | ||||
| Cash Per Share | 7.42 X | ||||
| Total Debt | 7.77 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 28.99 X | ||||
| Book Value Per Share | 6.31 X | ||||
| Cash Flow From Operations | (18.73 M) | ||||
| Short Ratio | 16.65 X | ||||
| Earnings Per Share | (1.08) X | ||||
| Target Price | 18.0 | ||||
| Number Of Employees | 82 | ||||
| Beta | 1.41 | ||||
| Market Capitalization | 231.98 M | ||||
| Total Asset | 226.62 M | ||||
| Retained Earnings | (52.31 M) | ||||
| Working Capital | 195.62 M | ||||
| Current Asset | 93.04 M | ||||
| Current Liabilities | 6.29 M | ||||
| Net Asset | 226.62 M |
About XBiotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze XBiotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of XBiotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of XBiotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for XBiotech Stock Analysis
When running XBiotech's price analysis, check to measure XBiotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XBiotech is operating at the current time. Most of XBiotech's value examination focuses on studying past and present price action to predict the probability of XBiotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XBiotech's price. Additionally, you may evaluate how the addition of XBiotech to your portfolios can decrease your overall portfolio volatility.